US2020262899A1PendingUtilityA1
Fc VARIANTS WITH ALTERED BINDING TO FcRn
Est. expiryDec 26, 2027(~1.4 yrs left)· nominal 20-yr term from priority
C07K 2317/76C07K 2317/21C07K 16/2866C07K 14/7151C07K 16/22C07K 2319/30C07K 16/4291A61K 2039/505C07K 16/32C07K 2317/52C07K 2317/524C07K 2317/24C07K 16/2896C07K 2317/526C07K 16/2863C07K 16/082C07K 16/18C07K 16/241C07K 16/2893Y02A50/30C07K 2317/90A61P 25/00C07K 2319/32A61P 35/00A61P 11/06C07K 2317/72A61P 19/02A61P 31/00A61P 17/06A61P 29/00C07K 2317/71A61P 37/02C07K 2317/92
69
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
Claims
exact text as granted — not AI-modified1 .- 7 . (canceled)
8 . In a method of treating a patient by administering an anti-C5 antibody with an Fc domain, the improvement comprising said Fc domain comprising amino acid substitutions M428L/N434S as compared to a human Fc polypeptide, wherein numbering is according to the EU index in Kabat et al., wherein said anti-C5 antibody with said amino acid substitutions has increased in vivo half-life as compared to said antibody without said substitutions.Join the waitlist — get patent alerts
Track US2020262899A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.